• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>CNS neuroscience & therapeutics. >Clinical Effectiveness of Rivastigmine Monotherapy and Combination Therapy in Alzheimer's Patients
【24h】

Clinical Effectiveness of Rivastigmine Monotherapy and Combination Therapy in Alzheimer's Patients

机译：利伐斯明单药和联合疗法在阿尔茨海默氏病中的临床疗效

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary Background Rivastigmine is an acetylcholinesterase inhibitor; the genotype data seen alongside the phenotype data explain the mutation or the molecular genetics involved and also help to relate the phenotype of an individual with their genotype. Aim To determine the clinical effectiveness of CYP 2D6, CYP 3A4, CYP 2C9/19, and UGT polymorphism on the steady‐state plasma concentrations and therapeutic outcome of rivastigmine monotherapy and combination therapy in patients with Alzheimer's disease. Result In this study, a significant allele frequency was observed for CYP 2D6*3 polymorphism in patients under rivastigmine combination therapy ( A del = 0.50 [patients] and A del = 0.20 [controls]), UGT 2B7 (T = 0.17 [patients] and 0.33 [Controls], and UGT 1A9*5 A = 0.58 [patients] and 0.26 [Controls]). The drug levels and P value of respondersonresponders were found to be 0.17 ± 0.08/0.22 ± 0.16 and 0.574 for rivastigmine and 0.18 ± 0.11/0.66 ± 0.63 and 0.009 for rivastigmine in combination therapy and 1.40 ± 0.65/0.59 ± 0.84 and 0.05 for memantine in combination therapy. Conclusion Poor metabolizer subjects of UGT 2B7 polymorphism in patients under rivastigmine combination therapy have higher drug levels with a poor response to the drug treatments.
机译：概述背景Rivastigmine是一种乙酰胆碱酯酶抑制剂。在表型数据旁边看到的基因型数据可以解释涉及的突变或分子遗传学，也有助于将个体的表型与其基因型相关联。目的确定CYP 2D6，CYP 3A4，CYP 2C9 / 19和UGT基因多态性对阿尔茨海默氏病患者稳态血药浓度和卡巴拉汀单药联合治疗的疗效。结果在这项研究中，在使用rivastigmine联合疗法的患者中观察到CYP 2D6 * 3多态性的显着等位基因频率（A> del = 0.50 [患者]，A> del = 0.20 [对照]），UGT 2B7（T = 0.17 [患者]和0.33 [对照组]，以及UGT 1A9 * 5 A = 0.58 [患者]和0.26 [对照组]）。对于卡巴拉汀而言，药物的反应水平和应答者/无应答者的P值分别为0.17±0.08 / 0.22±0.16和0.574，对于卡巴拉汀而言为0.18±0.11 / 0.66±0.63和0.009，对于联合治疗为1.40±0.65 / 0.59±0.84和0.05美金刚在联合疗法中。结论rivastigmine联合治疗的患者中UGT 2B7基因多态性较差的患者药物水平较高，对药物治疗的反应较差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号